What patent was challenged for oxybutynin gel in the 2010s?
In the 2010s, oxybutynin gel patent disputes centered on challenges to the patents covering the drug’s formulation/product and the conditions under which generic or “follow-on” products could be marketed. These cases generally played out as patent-eligibility and infringement fights tied to whether an applicant could obtain approval to launch a competing oxybutynin gel before the relevant patents expired.
Your question sounds like it may be looking for a specific case name or docket number (the “who vs. whom” and the exact asserted patents). The details needed for that (jurisdiction, brand vs. generic, and whether you mean Hatch-Waxman/ANDA-type litigation in the US or another forum) are not provided here.
Was this part of an ANDA/Hatch-Waxman-style generic challenge?
Most 2010s patent challenges involving a marketed brand drug like oxybutynin gel typically used a regulatory pathway where the challenger files a marketing application and simultaneously litigates (or contests) patent rights so it can launch earlier than the patent holder wants. If you tell me the country (US vs. EU, etc.) and the brand/generic name you’re referring to, I can map the likely procedural track and what issues were usually at stake in that type of litigation.
Which outcomes mattered: invalidation, non-infringement, or delayed launch?
Across oxybutynin gel patent challenges in this era, the outcome that mattered for launch timing was usually one of these:
- The asserted patents were found invalid or not infringed, clearing the way for earlier entry.
- The court found likely infringement/validity, delaying launch until patent protection ended or a later decision/settlement changed the timeline.
- Parties settled on licensing or an agreed entry date even if the merits were unresolved.
How long are these patents/exclusivities typically relevant for a 2010s gel product dispute?
Patent and exclusivity timing is case-specific and depends on:
- The filing/priority dates for the specific patent(s) asserted.
- Whether any listed patents are eligible for patent-term adjustments and what changes were made during prosecution.
- Whether regulatory exclusivities (if any) apply in the relevant jurisdiction.
- Settlement terms that effectively set an entry date even without a final merits ruling.
Which side effects or patient concerns often drive demand for oxybutynin gel competitors?
Oxybutynin is associated with anticholinergic adverse effects that often motivate patients to seek different formulations (including gels) that may affect tolerability. When competitors are blocked or delayed by patent disputes, patient and clinician attention often focuses on access and comparative tolerability rather than only patent law.
If you want, share any of the following and I’ll narrow to the exact 2010s oxybutynin gel patent challenge(s):
1) the jurisdiction (US?),
2) the brand name (if you know it),
3) the company on either side (brand holder or challenger),
4) the patent number(s) or a case caption/docket.
Sources
None provided in the prompt.